Table 1.
Baseline demographic and patients characteristics
| SP (n=54) | VP (n=54) | P value | |
|---|---|---|---|
| Gender, n (%) | 1 | ||
| Male | 42 (77.8) | 43 (79.6) | |
| Female | 12 (22.2) | 11 (20.4) | |
| Age, median (range) | 60 (39–73) | 62 (37–74) | 0.073 |
| Stage, n(%) | 1 | ||
| IIIA | 22 (40.7) | 22 (40.7) | |
| IIIB | 32 (59.3) | 32 (59.3) | |
| Primary site | 0.478 | ||
| Right upper lobe | 28 (51.9) | 21 (38.9) | |
| Right middle lobe | 0 (0.0) | 2 (3.7) | |
| Right lower lobe | 2 (3.7) | 3 (5.6) | |
| Left upper lobe | 18 (33.3) | 23 (42.6) | |
| Left lower lobe | 3 (5.6) | 4 (7.4) | |
| Others | 3 (5.6) | 1 (1.9) | |
| Histology, n (%) | 0.92 (adeno versus non-adeno) | ||
| Adenocarcinoma | 30 (55.6) | 30 (55.6) | |
| Squamous cell carcinoma | 17 (31.5) | 17 (31.5) | |
| Adenosquamous cell carcinoma | 1 (1.9) | 0 (0.0) | |
| Large-cell carcinoma | 2 (3.7) | 1 (1.9) | |
| Others | 4 (7.4) | 6 (11.1) | |
| Smoking status, n (%) | 1 | ||
| Never | 6 (11.1) | 7 (13.0) | |
| Ever | 48 (88.9) | 47 (87.0) | |
| PS, n (%) | 0.694 | ||
| 0 | 34 (63.0) | 31 (57.4) | |
| 1 | 20 (37.0) | 23 (42.6) | |
| Complication, n (%) | 0.335 | ||
| Absent | 29 (53.7) | 23 (42.6) | |
| Present | 25 (46.3) | 31 (57.4) | |
| Lung V20 (%), median (range) | 23.5 (13.1–34.7) | 25.2 (11.4–34.7) | 0.306 |
SP cisplatin plus S-1, VP cisplatin plus vinorelbine, PS performance status